These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16736950)

  • 21. Clinical implications of HIV drug resistance to nucleoside and nucleotide reverse transcriptase inhibitors.
    Geretti AM
    AIDS Rev; 2006; 8(4):210-20. PubMed ID: 17219736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral genotypic resistance in plasma RNA and whole blood DNA in HIV-1 infected patients failing HAART.
    Saracino A; Gianotti N; Marangi M; Cibelli DC; Galli A; Punzi G; Monno L; Lazzarin A; Angarano G;
    J Med Virol; 2008 Oct; 80(10):1695-706. PubMed ID: 18712823
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines.
    de Mendoza C; Anta L; García F; Pérez-Elías MJ; Gutiérrez F; Llibre JM; Menéndez-Arias L; Dalmau D; Soriano V
    AIDS Rev; 2009; 11(1):39-51. PubMed ID: 19290033
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenomics of HIV.
    Ast O; Lüke W
    Curr Opin Mol Ther; 2004 Jun; 6(3):302-7. PubMed ID: 15264433
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
    Fox ZV; Geretti AM; Kjaer J; Dragsted UB; Phillips AN; Gerstoft J; Staszewski S; Clotet B; von Wyl V; Lundgren JD
    AIDS; 2007 Oct; 21(15):2033-42. PubMed ID: 17885293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
    Cozzi-Lepri A; Phillips AN; Ruiz L; Clotet B; Loveday C; Kjaer J; Mens H; Clumeck N; Viksna L; Antunes F; Machala L; Lundgren JD;
    AIDS; 2007 Mar; 21(6):721-32. PubMed ID: 17413693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of an in-house genotyping resistance test for HIV-1 drug resistance interpretation and genotyping.
    Chen JH; Wong KH; Chan K; Lam HY; Lee SS; Li P; Lee MP; Tsang DN; Zheng BJ; Yuen KY; Yam WC
    J Clin Virol; 2007 Jun; 39(2):125-31. PubMed ID: 17449318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluating the therapeutic care of HIV infection in Tunisia].
    Jlizi A; Slim A; Benammar Elgaaied A; Ben Rejab S; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M
    Tunis Med; 2008 Jun; 86(6):534-9. PubMed ID: 19216443
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
    Deforche K; Cozzi-Lepri A; Theys K; Clotet B; Camacho RJ; Kjaer J; Van Laethem K; Phillips A; Moreau Y; Lundgren JD; Vandamme AM;
    Antivir Ther; 2008; 13(3):399-407. PubMed ID: 18572753
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1.
    Garcia-Perez J; Sanchez-Palomino S; Perez-Olmeda M; Fernandez B; Alcami J
    J Med Virol; 2007 Feb; 79(2):127-37. PubMed ID: 17177310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand.
    Poonpiriya V; Sungkanuparph S; Leechanachai P; Pasomsub E; Watitpun C; Chunhakan S; Chantratita W
    J Virol Methods; 2008 Jul; 151(1):79-86. PubMed ID: 18462814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV genotypic resistance testing to optimize antiretroviral prescribing: is there room for improvement?
    Uy J; Brooks JT; Baker R; Hoffman M; Moorman A; Novak R;
    Antivir Ther; 2007; 12(6):957-62. PubMed ID: 17926650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV-1 drug resistance in variants from the female genital tract and plasma.
    Kemal KS; Burger H; Mayers D; Anastos K; Foley B; Kitchen C; Huggins P; Schroeder T; Picchio G; Back S; Gao W; Meyer WA; Weiser B
    J Infect Dis; 2007 Feb; 195(4):535-45. PubMed ID: 17230413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes.
    Holguín A; Ramirez de Arellano E; Rivas P; Soriano V
    AIDS Rev; 2006; 8(2):98-107. PubMed ID: 16848277
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The use of drug resistance algorithms and genotypic inhibitory quotient in prediction of lopinavir-ritonavir treatment response in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
    Maillard A; Chapplain JM; Tribut O; Bentué-Ferrer D; Tattevin P; Arvieux C; Michelet C; Ruffault A
    J Clin Virol; 2007 Feb; 38(2):131-8. PubMed ID: 17208042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences of nine drug resistance interpretation systems in predicting short-term therapy outcomes of treatment-experienced HIV-1 infected patients: a retrospective observational cohort study.
    Helm M; Walter H; Ehret R; Schmit JC; Kurowski M; Knechten H; Korn K; Braun P; Schmidt B
    Eur J Med Res; 2007 Jun; 12(6):231-42. PubMed ID: 17666312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surveillance of genotypic resistance mutations in chronic HIV-1 treated individuals after completion of the National Access to Antiretroviral Program in Thailand.
    Sukasem C; Churdboonchart V; Chasombat S; Kohreanudom S; Watitpun C; Pasomsub E; Piroj W; Tiensuwan M; Chantratita W
    Infection; 2007 Apr; 35(2):81-8. PubMed ID: 17401711
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mining complex genotypic features for predicting HIV-1 drug resistance.
    Saigo H; Uno T; Tsuda K
    Bioinformatics; 2007 Sep; 23(18):2455-62. PubMed ID: 17698858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.